Welcome to our dedicated page for Emmaus Life Scie SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing SEC filings for a rare disease biopharmaceutical company requires understanding the unique financial dynamics of orphan drug development. Emmaus Life Sciences (EMMA) files regulatory documents that reveal its commercial progress with Endari, its sickle cell disease treatment.
The company's 10-K annual reports disclose revenue from Endari sales, research and development expenditures, and the financial realities of marketing a specialty pharmaceutical product to a defined patient population. For biotech investors, these filings illuminate cash runway, operating expenses, and the balance between commercialization costs and product revenue.
Quarterly 10-Q filings track Emmaus Life Sciences' financial trajectory between annual reports. These documents show prescription trends, gross-to-net adjustments common in pharmaceutical accounting, and any changes to the company's cash position. Our AI summaries extract these metrics without requiring you to parse complex pharmaceutical revenue recognition disclosures.
Form 8-K material event filings announce significant developments: regulatory decisions affecting Endari, strategic transactions, leadership changes, or material agreements. For a small-cap biotech, these current reports often contain the most market-moving information.
Form 4 insider transactions reveal when executives and directors buy or sell EMMA shares. Tracking these filings helps identify whether company leadership is increasing or decreasing their personal stakes. Our platform flags these transactions automatically so you can monitor insider activity without manually checking SEC EDGAR.
DEF 14A proxy statements detail executive compensation structures, board composition, and governance matters. For smaller pharmaceutical companies, understanding management incentives and their alignment with shareholder interests provides useful context for evaluating the investment.
Emmaus Life Sciences entered into a License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) giving NIT exclusive rights to market, sell, and distribute Endari and its generic equivalents for sickle cell disease in the U.S., its territories, and Canada. In return, Emmaus receives an upfront payment and ongoing royalties on NIT’s product sales.
Once the agreement’s “Effective Date” occurs, Emmaus will also become NIT’s exclusive supplier of Endari for this use and region at a price based on Emmaus’ production cost plus an agreed margin. The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and the agreement can be terminated if these are not met by October 1, 2026. If NIT does not achieve specified minimum annual sales after the Effective Date, its rights become nonexclusive, while Emmaus keeps all Endari rights outside this disease area and territory.
Emmaus Life Sciences, Inc. entered into an exchange agreement with a single noteholder on December 17, 2025. The company agreed to issue 6,332,692 shares of common stock valued at approximately $0.38 per share and a new convertible promissory note with a principal amount of
The cancelled note carried 10% annual interest and was convertible at $0.13 per share. The new note also bears 10% annual interest and is initially convertible at $0.01 per share, subject to quarterly reset to the average VWAP if that is lower, and to adjustment for stock splits and similar events. The principal on the new note is due on demand, and no additional cash consideration was exchanged. The securities will be issued without registration in reliance on the Section 3(a)(9) exemption.
Emmaus Life Sciences, Inc. reported a board change, disclosing that director Ian Zwicker resigned from the company’s board of directors on December 15, 2025, with the resignation to take effect on December 31, 2025. The filing does not describe any related financial effects or changes to the company’s operations, focusing solely on this governance update. Emmaus remains a Delaware corporation headquartered in Torrance, California, and the report was signed by Chairman and Chief Executive Officer Willis Lee.
Emmaus Life Sciences filed its Q3 2025 10-Q, highlighting a sharp revenue decline and liquidity strain alongside a going concern warning. Q3 revenue was $3.38 million versus $5.48 million a year ago, and the company posted a net loss of $2.08 million versus net income of $1.83 million in Q3 2024. Operating profit of $0.70 million was outweighed by other expense of $2.19 million, driven mainly by interest expense of $1.93 million.
For the nine months, revenue was $8.60 million versus $13.36 million. Cash was $0.29 million with current liabilities of $64.17 million, and total liabilities of $80.24 million against assets of $20.76 million, resulting in a stockholders’ deficit of $59.49 million. Management states there is substantial doubt about continuing as a going concern without restructuring debt and raising additional financing. The company also recorded a $0.53 million realized loss year‑to‑date on its Telcon convertible bond.
FAQ
What is the current stock price of Emmaus Life Scie (EMMA)?
What is the market cap of Emmaus Life Scie (EMMA)?
